Vaccines MDPI

🎉 We are excited to announce the publication of the first paper in our special issue "Mechanisms of Inflammation in Long-COVID/Post-COVID-Vaccination Syndrome"! 📚

📝 "Autoimmune Features of Post-COVID-19 Vaccination Syndrome and Their Impacts on the Renin–Angiotensin System," authored by Paolo Bellavite, Giuseppe Di Fede, Mauro Mantovani and Elisabetta Zanolin.

👉 We invite you to read the full article here: https://brnw.ch/21x2tuk 🌟

This special issue, led by Dr. Loredana Frasca, is still welcoming submissions! ✍️

For more information about the special issue, please visit: https://brnw.ch/21x2tuj 🌐

Autoimmune Features of Post-COVID-19 Vaccination Syndrome and Their Impacts on the Renin–Angiotensin System One of the most critical aspects of post-acute COVID-19 syndrome (PACS) and post-acute COVID-19 vaccination syndrome (PACVS) is the presence of autoantibodies. These autoantibodies are directed against various receptors in the autonomic and cardiovascular systems, including those targeting proteins ...

🏆 Editor’s Choice

Evaluating the Immunogenicity, Efficacy, and Effectiveness of Recombinant Zoster Vaccine for Global Public Health Policy

by Lucy R. Williams, Joachim Hombach and Melanie Marti

The recombinant zoster vaccine (RZV) is effective in reducing the risk of HZ and its associated complications. Protection is long-lasting and the vaccine is suitable for older and immunocompromised populations. However, the decision to incorporate the vaccine into national policies depends on additional factors (e.g., cost-effectiveness), which may be difficult to characterize without an understanding of the global disease burden.

🔗 Read the full text here: https://brnw.ch/21x2tlT

Evaluating the Immunogenicity, Efficacy, and Effectiveness of Recombinant Zoster Vaccine for Global Public Health Policy Background: Herpes zoster (HZ) is a painful neurocutaneous disease caused by the varicella-zoster virus. The recombinant zoster vaccine (RZV) is becoming increasingly incorporated into national vaccination schedules. We aimed to evaluate RZV from a global public health policy perspective. Methods: W...

🏆 Editor’s Choice

Pre-Existing Anti-Vector Immunity to Adenovirus-Inspired VLP Vaccines Shows an Adjuvant-Dependent Antagonism

By Salomé Gallet, Dalil Hannani, Sebastian Dergan-Dylon,
Emilie Vassal-Stermann, Isabelle Bally, Christopher Chevillard,
Daphna Fenel, Olivier Epaulard, Pascal Poignard and Pascal Fender.

The data suggest that the immune status against immunizing VLPs must be taken into consideration when designing immunization protocols. Importantly, the effects of prior immunity may vary depending on the nature of the protocol, including factors such as adjuvant use.

🔗 Read the full article: https://brnw.ch/21x2rRo

Pre-Existing Anti-Vector Immunity to Adenovirus-Inspired VLP Vaccines Shows an Adjuvant-Dependent Antagonism Background/Objectives: The use of virus-like particles (VLPs) in vaccinology has expanded significantly in recent years. VLPs have the advantage of being non-infectious while effectively stimulating B cell responses through the repetitive presentation of epitope motifs on their surface. Since VLPs a...

📢 Special Issue Update – Vaccines

We are pleased to share that 5 articles have already been published in the Special Issue "Immunobiology of Mycobacterium tuberculosis and Its Implication in Vaccine Design".

The issue remains open for submissions, we invite you to contribute your research to this growing collection.

👤 Guest Editors: Dr. Tony W. Ng and Prof. Dr. Steven A. Porcelli

We invite authors to submit work that they view as relevant to these goals, including, but not limited to, the following topics:

1. Intravenous BCG and other nontraditional routes of vaccine administration.
2. Newly recognized TB antigens, including subdominant and cryptic antigens or antigenic decoys.
3. Adjuvant formulations.
4. Eradicating dormant and persistent forms of Mtb.
5. Prime-boost vaccination with attenuated Mtb or BCG strains.
6. Mycobacterium-specific T and B cell responses.

📅 Deadline for manuscript submissions: 31 August 2026
🔗 View published articles & submit your work: https://brnw.ch/21x2rsU

Immunobiology of Mycobacterium tuberculosis and Its Implication in Vaccine Design Vaccines, an international, peer-reviewed Open Access journal.